Cargando…
Duration of antithyroid drug treatment may predict weight gain after radioactive iodine therapy in patients with Graves’ disease
BACKGROUND: Weight gain post-radioiodine (RAI) treatment is observed in patients with hyperthyroid Graves’ disease. Previous studies, mostly in Caucasian patients, demonstrated excessive weight gain averaging 5–7 kg from initial presentation. AIM: The aim of this study was to determine the extent an...
Autores principales: | Yotsapon, Thewjitcharoen, Waralee, Chatchomchuan, Hussamon, Prasatkaew, Panita, Srichomchey, Siriwan, Butadej, Soontaree, Nakasatien, Ekgaluck, Wanothayaroj, Rajata, Rajatanavin, Thep, Himathongkam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124706/ https://www.ncbi.nlm.nih.gov/pubmed/35615430 http://dx.doi.org/10.1016/j.heliyon.2022.e09471 |
Ejemplares similares
-
Profile of Levothyroxine Replacement Therapy in Graves’ Disease Patients with Hypothyroidism Post-Radioactive Iodine Ablation: Focus on Different Weight-Based Regimens
por: Mathiphanit, Saravut, et al.
Publicado: (2022) -
Serum T3 Level and Duration of Minimum Maintenance Dose Therapy Predict Relapse in Methimazole-Treated Graves Disease
por: Thewjitcharoen, Yotsapon, et al.
Publicado: (2020) -
Impact of first-line treatment choice on long-term outcomes of hyperthyroid Graves’ disease patients with thyrotoxic periodic paralysis
por: Karndumri, Krittadhee, et al.
Publicado: (2020) -
Prevalence and characteristics of misdiagnosed adult-onset type 1 diabetes mellitus in Thai people by random plasma C-peptide testing
por: Thewjitcharoen, Yotsapon, et al.
Publicado: (2023) -
ODP531 Worsening of pretibial myxedema following repeated doses of radioiodine treatment in a patient with hyperthyroid Graves’ disease
por: Thewjitcharoen, Yotsapon, et al.
Publicado: (2022)